Molecular radiology is a specialty that uses compounds called radiopharmaceuticals to detect and treat disease. Radiopharmaceuticals are made by attaching a specialized biological compound to a radioactive molecule called a radionuclide. Depending on the type of compound, the radiopharmaceutical will go to different tissues in your body such as liver, bones, kidneys, thyroid, etc. The radiopharmaceutical is taken up by injured or diseased tissue in different amounts than in surrounding healthy tissue. This difference can be detected on specialized scanners or can be used to treat disease.
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has created a video on the value of Molecular Radiology. The video below highlights several specific examples—with corresponding evidence—of how nuclear radiology and molecular imaging are helping patients with cancer, heart disease, and other diseases.
In a molecular radiology study, each radiopharmaceutical is targeted to a specific organ, such as bone or liver. The radiopharmaceutical may be injected, swallowed or inhaled as a gas. A special scanner is then used to image areas in the body that contain the radiopharmaceutical. The images produced by the scanner are interpreted by a radiologist who specializes in interpreting molecular radiology studies.
Yes. The radiation doses used in molecular radiology are similar to that of other imaging examinations, and have been proven safe and effective over many decades of use. The molecular radiologist and technologist are trained in radiation safety procedures. All radiopharmaceuticals are manufactured under strict government standards and are administered in the smallest possible amounts needed to achieve quality imaging results. The radioactivity is quickly eliminated from your body usually within 24 hours after the test is completed. The risk of allergic reaction to the radiopharmaceutical is very low; no more than 2-3 reactions per 100,000 studies.
In general, pregnant women should be careful about undergoing imaging studies that use ionizing radiation, including X-ray, CT, and molecular radiology studies. Even though the levels of radiation used are low, there still may be a risk to the developing baby. Only in cases where the benefit clearly outweighs the risk should pregnant women undergo molecular radiology exams.
The radiopharmaceuticals used in these studies may be excreted in breastmilk and could put nursing infants at risk. Therefore a breastfeeding woman should stop nursing for a period of time following a Molecular Radiology exam to allow the radiopharmaceutical to clear from her body. The amount of time needed to clear from the body varies for each specific radiopharmaceutical, lasting anywhere from a few hours to a few days. During that period, the woman is advised to express and discard her breastmilk. Once the radiopharmaceutical clears from the system, it’s safe to return to breastfeeding. The technologist or radiologist will provide information regarding the amount of time needed for the specific radiopharmaceutical that was given.
Bone & Joint Imaging
Gastric Emptying Scan
Gastrointestinal Bleeding Scan
Heat Damaged Red Blood Cell Scan
Lymphoscintigraphy – lymphatic drainage
Lymphoscintigraphy – Sentinel Node
Meckel’s Diverticulum Scan
Radioiodine Thyroid Scan
Radioiodine Whole Body Scan
Radioiodine Therapy (I-131)
Radionuclide Ventriculogram (MUGA)
White Blood Cell Scan